Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified

被引:42
|
作者
Ward, RL
Turner, J
Williams, R
Pekarsky, B
Packham, D
Velickovic, M
Meagher, A
O'Connor, T
Hawkins, NJ
机构
[1] St Vincents Hosp, Dept Med Oncol, Darlinghurst, NSW 2010, Australia
[2] St Vincents Hosp, Dept Colorectal Surg, Darlinghurst, NSW 2010, Australia
[3] St Vincents Hosp, Dept Pathol Anat, Darlinghurst, NSW 2010, Australia
[4] Univ New S Wales, Sch Med, Sydney, NSW 2052, Australia
[5] Univ Adelaide, Ctr Hlth Informat, Adelaide, SA, Australia
[6] Univ Adelaide, Dept Gen Practice, Adelaide, SA, Australia
来源
JOURNAL OF PATHOLOGY | 2005年 / 207卷 / 04期
关键词
colorectal cancer; mismatch repair; prognosis; chemotherapy;
D O I
10.1002/path.1851
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study prospectively examines the accuracy of immunohistochemical staining in the identification of mismatch repair detective (MMRD) colorectal cancer in routine clinical practice. The potential impact of this information on decisions regarding adjuvant treatment and germline testing were quantified. A consecutive series of fresh tissue (836 cancers) was obtained from 786 individuals undergoing curative surgery for colorectal cancer at one institution. As part of normal practice, each tumour was screened for the expression of MLH1 and MSH2 by immunohistochemical staining (IHC) and relevant clinicopathological details were documented. Microsatellite instability (MSI) was assessed using standard markers. Overall, 108 (13%) tumours showed loss of staining for either MLH1 (92 tumours) or MSH2 (16 tumours). The positive predictive value of mismatch repair IHC when used alone in the detection of MSI tumours was 88%, and the negative predictive value was 97%. Specificity and positive predictive value were improved by correlation with microsatellite status. Tumour stage (HR 3.5, 95% CI 2.0-6.0), vascular space invasion (HR 1.9, 95% CI 1.2-3.0) and mismatch repair deficiency (HR 0.2, 95% CI 0.05-0.87) were independent prognostic factors in stages II and III disease. Screening by mismatch repair IHC could reasonably have been expected to prevent ineffective treatment in 3.6% of stage II and 7.6% of stage III patients. The frequency of germline mismatch repair mutations was 0.8%, representing six unsuspected hereditary non-polyposis colorectal cancer (HNPCC) cases. Routine screening of colorectal cancers by mismatch repair IHC identifies individuals at low risk of relapse, and can prevent unnecessary adjuvant treatments in a significant number of individuals. Abnormal immunohistochemistry should be confirmed by microsatellite testing to ensure that false-positive results do not adversely impact on treatment decisions. Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:377 / 384
页数:8
相关论文
共 50 条
  • [1] Mismatch repair deficiency in sporadic synchronous colorectal cancer
    Brueckl, WM
    Limmert, T
    Brabletz, T
    Guenther, K
    Jung, A
    Hermann, K
    Wiest, GH
    Kirchner, T
    Hohenberger, W
    Hahn, EG
    Wein, A
    [J]. ANTICANCER RESEARCH, 2000, 20 (6C) : 4727 - 4732
  • [2] Re:: Ward et al.: Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified.: J Pathol 2005;207:377-384
    Jass, JR
    [J]. JOURNAL OF PATHOLOGY, 2006, 208 (04): : 590 - 591
  • [3] Mismatch Repair Deficiency in Sporadic Colorectal Cancers
    任舒月
    陈春生
    任常山
    [J]. Chinese Medical Sciences Journal, 1998, (02) : 127 - 127
  • [4] DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome
    Poulogiannis, George
    Frayling, Ian M.
    Arends, Mark J.
    [J]. HISTOPATHOLOGY, 2010, 56 (02) : 167 - 179
  • [5] Re:: Ward et al.: Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified.: J Pathol 2005;207:377-384 -: Authors' reply
    Ward, R
    Turner, J
    Hawkins, N
    [J]. JOURNAL OF PATHOLOGY, 2006, 208 (04): : 592 - 592
  • [6] Consequences of testing for mismatch repair deficiency of colorectal cancer in clinical practice
    Leicher, L. W.
    Lammertink, M. H. A.
    Offerman, S. R.
    Morreau, H.
    de Jong, M. M.
    de Groot, J. W. B.
    van Westreenen, H. L.
    Vasen, H. F. A.
    Cappel, W. H. de Vos Tot Nederveen
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2018, 53 (05) : 632 - 636
  • [7] SCREENING FOR MISMATCH REPAIR DEFICIENCY IN COLORECTAL CANCER
    Delahunty, R.
    McMurrick, P.
    Carne, P.
    Shapiro, J.
    Oliva, K.
    Wilkins, S.
    Baranyai, E.
    Antill, Y. C.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 52 - 52
  • [8] Immunotherapy in Colorectal Cancer With Mismatch Repair Deficiency
    Overman, Michael J.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 265 - 267
  • [9] Mismatch repair protein deficiency assessed by immunohistochemistry in sporadic colorectal carcinoma
    Adhikari, Cynthia
    Bandyopadhyay, Ranjana
    Bandyopadhyay, Ujjwal
    Sarkar, Snigdha
    Basu, Keya
    [J]. INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2023, 66 (02) : 252 - 257
  • [10] Microstatellite Instability and DNA Mismatch Repair Protein Deficiency in Chinese Patients with Sporadic Colorectal Cancer
    Huang, D.
    Chen, X.
    Yu, B.
    Sheng, W.
    Du, X.
    [J]. LABORATORY INVESTIGATION, 2013, 93 : 156A - 156A